jRCT1031250108招募中不适用
Effects of sacubitril-valsartan on cardiac function and body fluid volume in peritoneal dialysis patients
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Novartis
- 入组人数
- 20
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients who meet all of the following criteria will be included.
- •Adult patients, regardless of gender, who visit the Department of Nephrology at Yamanashi University Hospital and have been undergoing peritoneal dialysis for at least six months.
- •Peritoneal dialysis patients with hypertension.
- •Patients who can provide written informed consent to participate in this study. Consent must be given by the individual.
排除标准
- •1.Patients who meet the contraindications for sacubitril valsartan
- •2.Patients who were taking sacubitril valsartan before enrollment in the study
- •3.If a doctor determines that the person is unsuitable for the program
结局指标
主要结局
-
Changes in LVEF 3 and 6 months after taking Sacubitril Valsartan compared to before administration
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
DMedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2018-000368-27-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE14
进行中（未招募）
1 期
/AEUCTR2014-001090-14-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)270
进行中（未招募）
不适用
/AEUCTR2005-000086-19-SEAlcon Sverige AB300
进行中（未招募）
不适用
/AEUCTR2004-002470-31-ESHospital Universitario Gregorio Marañón
进行中（未招募）
不适用
/AMedDRA version: 14.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000045-12-FRCentre François Baclesse